KidneyCAN shared on X:
“How do researchers make promising new treatments safer and more manageable for patients?
Rana McKay from UC San Diego discusses emerging research on the next-generation HIF-2 inhibitor casdatifan, what researchers are learning about managing side effects, and why she’s optimistic about the future of kidney cancer treatment.”
You can also read:
ARC-20 Study: Casdatifan in Refractory Clear Cell Renal Cell Carcinoma
